162 related articles for article (PubMed ID: 37524201)
1. Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab/cilgavimab) in healthy Japanese adults.
Okada H; Ishikawa K; Itoh Y; Noda Y; Eto T; Pilla Reddy V; Chen CC; Gibbs M; Johnsson E
J Infect Chemother; 2023 Nov; 29(11):1061-1067. PubMed ID: 37524201
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
Forte-Soto P; Albayaty M; Brooks D; Arends RH; Tillinghast J; Aksyuk AA; Bouquet J; Chen C; Gebre A; Kubiak RJ; Pilla Reddy V; Seegobin S; Streicher K; Templeton A; Esser MT
J Infect Dis; 2023 May; 227(10):1153-1163. PubMed ID: 36683419
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
Levin MJ; Ustianowski A; De Wit S; Launay O; Avila M; Templeton A; Yuan Y; Seegobin S; Ellery A; Levinson DJ; Ambery P; Arends RH; Beavon R; Dey K; Garbes P; Kelly EJ; Koh GCKW; Near KA; Padilla KW; Psachoulia K; Sharbaugh A; Streicher K; Pangalos MN; Esser MT;
N Engl J Med; 2022 Jun; 386(23):2188-2200. PubMed ID: 35443106
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
Levin MJ; Ustianowski A; De Wit S; Beavon R; Thissen J; Seegobin S; Dey K; Near KA; Streicher K; Kiazand A; Esser MT
Infect Dis Ther; 2024 Jun; 13(6):1253-1268. PubMed ID: 38703336
[TBL] [Abstract][Full Text] [Related]
5. Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
Hobbs FDR; Montgomery H; Padilla F; Simón-Campos JA; Arbetter D; Seegobin S; Kiazand A; Streicher K; Martinez-Alier N; Cohen TS; Esser MT
Infect Dis Ther; 2024 Mar; 13(3):521-533. PubMed ID: 38403865
[TBL] [Abstract][Full Text] [Related]
6. Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
Hobbs FDR; Montgomery H; Padilla F; Simón-Campos JA; Kim K; Arbetter D; Padilla KW; Reddy VP; Seegobin S; Streicher K; Templeton A; Viani RM; Johnsson E; Koh GCKW; Esser MT
Infect Dis Ther; 2023 Sep; 12(9):2269-2287. PubMed ID: 37751015
[TBL] [Abstract][Full Text] [Related]
7. Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
Clegg LE; Stepanov O; Schmidt H; Tang W; Zhang H; Webber C; Cohen TS; Esser MT; Någård M
Antimicrob Agents Chemother; 2024 May; 68(5):e0158723. PubMed ID: 38534112
[TBL] [Abstract][Full Text] [Related]
8. Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection.
Bender Ignacio RA; Wohl DA; Arends R; Pilla Reddy V; Mu Y; Javan AC; Hughes MD; Eron JJ; Currier JS; Smith D; Chew KW; Gibbs M; Fletcher CV
Clin Pharmacol Ther; 2022 Dec; 112(6):1207-1213. PubMed ID: 35797235
[TBL] [Abstract][Full Text] [Related]
9. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.
Loo YM; McTamney PM; Arends RH; Abram ME; Aksyuk AA; Diallo S; Flores DJ; Kelly EJ; Ren K; Roque R; Rosenthal K; Streicher K; Tuffy KM; Bond NJ; Cornwell O; Bouquet J; Cheng LI; Dunyak J; Huang Y; Rosenbaum AI; Pilla Reddy V; Andersen H; Carnahan RH; Crowe JE; Kuehne AI; Herbert AS; Dye JM; Bright H; Kallewaard NL; Pangalos MN; Esser MT
Sci Transl Med; 2022 Mar; 14(635):eabl8124. PubMed ID: 35076282
[TBL] [Abstract][Full Text] [Related]
10. AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Levin MJ; Ustianowski A; Thomas S; Templeton A; Yuan Y; Seegobin S; Houlihan CF; Menendez-Perez I; Pollett S; Arends RH; Beavon R; Dey K; Garbes P; Kelly EJ; Koh GCKW; Ivanov S; Near KA; Sharbaugh A; Streicher K; Pangalos MN; Esser MT;
Clin Infect Dis; 2023 Apr; 76(7):1247-1256. PubMed ID: 36411267
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
Bender Ignacio RA; Chew KW; Moser C; Currier JS; Eron JJ; Javan AC; Giganti MJ; Aga E; Gibbs M; Tchouakam Kouekam H; Johnsson E; Esser MT; Hoover K; Neytman G; Newell M; Daar ES; Fischer W; Fletcher CV; Li JZ; Greninger AL; Coombs RW; Hughes MD; Smith D; Wohl DA;
JAMA Netw Open; 2023 Apr; 6(4):e2310039. PubMed ID: 37099295
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Montgomery H; Hobbs FDR; Padilla F; Arbetter D; Templeton A; Seegobin S; Kim K; Campos JAS; Arends RH; Brodek BH; Brooks D; Garbes P; Jimenez J; Koh GCKW; Padilla KW; Streicher K; Viani RM; Alagappan V; Pangalos MN; Esser MT;
Lancet Respir Med; 2022 Oct; 10(10):985-996. PubMed ID: 35688164
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
Tuffy KM; Ahani B; Aksyuk AA; Avila M; Brady T; Kijak GH; Koh G; Levin MJ; Roe TL; Schuko N; Thissen J; Ustianowski A; Zhang T; Kelly EJ; Streicher K
J Infect Dis; 2023 Oct; 228(8):1055-1059. PubMed ID: 37280116
[TBL] [Abstract][Full Text] [Related]
14. Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.
Kim JY; Jang YR; Hong JH; Jung JG; Park JH; Streinu-Cercel A; Streinu-Cercel A; Săndulescu O; Lee SJ; Kim SH; Jung NH; Lee SG; Park JE; Kim MK; Jeon DB; Lee YJ; Kim BS; Lee YM; Kim YS
Clin Ther; 2021 Oct; 43(10):1706-1727. PubMed ID: 34551869
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.
Pulvirenti F; Garzi G; Milito C; Sculco E; Sciannamea M; Napoli A; Cinti L; Roberto P; Punziano A; Carrabba M; Piano Mortari E; Carsetti R; Antonelli G; Quinti I
Front Immunol; 2023; 14():1249462. PubMed ID: 37954618
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
Aliprantis AO; Wolford D; Caro L; Maas BM; Ma H; Montgomery DL; Sterling LM; Hunt A; Cox KS; Vora KA; Roadcap BA; Railkar RA; Lee AW; Stoch SA; Lai E
Clin Pharmacol Drug Dev; 2021 May; 10(5):556-566. PubMed ID: 33125189
[TBL] [Abstract][Full Text] [Related]
17. Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
Kijak GH; Ahani B; Arbetter D; Chuecos F; Gopalakrishnan V; Beloor J; Brady T; Nguyen A; Roe TL; Schuko N; Zhang T; Hobbs FDR; Padilla F; Kelly EJ; Montgomery H; Streicher K
Infect Dis Ther; 2023 Dec; 12(12):2691-2707. PubMed ID: 37914983
[TBL] [Abstract][Full Text] [Related]
18. Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults.
Hao X; Zhang Z; Ma J; Cheng L; Ji Y; Liu Y; Zhao D; Zhang W; Li C; Yan L; Margolis D; Zhu Q; Zhang Y; Zhang F
Front Pharmacol; 2022; 13():983505. PubMed ID: 36147329
[No Abstract] [Full Text] [Related]
19. Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.
Kertes J; Shapiro Ben David S; Engel-Zohar N; Rosen K; Hemo B; Kantor A; Adler L; Shamir Stein N; Mizrahi Reuveni M; Shahar A
Clin Infect Dis; 2023 Feb; 76(3):e126-e132. PubMed ID: 35904210
[TBL] [Abstract][Full Text] [Related]
20. Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring.
Brady T; Zhang T; Tuffy KM; Haskins N; Du Q; Lin J; Kaplan G; Novick S; Roe TL; Ren K; Rosenthal K; McTamney PM; Abram ME; Streicher K; Kelly EJ
Microbiol Spectr; 2022 Oct; 10(5):e0103422. PubMed ID: 35993765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
